SIGENP

Società Italiana di Gastroenterologia Epatologia e Nutrizione Pediatrica

  • Accedi
  • Home
  • News
  • Società
    Channel Consiglio Direttivo Commissioni Aree Comitato portale Sezioni regionali Rete Territoriale Statuto Bilanci Verbali Ufficio stampa
  • Formazione
    Calendario eventi residenziali Congresso Nazionale EDUCO Webinar SIGENP FAD SIGENP Calendario eventi patrocinati Richiedi patrocinio Archivio congressi Archivio Eventi Registrazioni eventi
  • Studi in corso
  • Giornale SIGENP
  • Pubblicazioni SIGENP
    Case report Linee guida Consensus statement Pubblicazioni soci Covid-19
  • Area pazienti
    Associazioni pazienti Articoli di interesse per i pazienti
  • Rassegna Stampa
  • Membership
  • Contatti
  • Passa al contenuto principale

SIGENP - Società Italiana di Gastroenterologia Epatologia e Nutrizione Pediatrica

Terapie emergenti nella celiachia: oltre la dieta senza glutine

NEW HORIZON FOR TREATMENT IN...

Emerging therapies for coeliac disease: beyond the gluten-free diet

Maria Boccia, Valentina Discepolo

European Laboratory for the Investigation of Food-Induced Diseases (ELFID), University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples, Italy.

Coeliac disease is a chronic immune-mediated enteropathy triggered by dietary gluten in genetically susceptible individuals. A strict gluten-free diet remains the only established effective and safe treatment. However, a life-long avoidance of gluten is difficult to achieve and maintain. Advances in disease pathogenesis have identified therapeutic targets at the luminal, epithelial and immune levels. Gluten-degrading enzymes are intended to reduce exposure to immunogenic peptides, whereas intestinal barrier modulators and tissue transglutaminase 2 inhibitors act before or during antigen presentation. Other agents target inflammatory pathways or aim to induce antigen-specific immune tolerance. Oral inhibition of tissue transglutaminase 2 has attenuated gluten-induced mucosal injury in a phase 2 trial, while engineered glutenases and tolerogenic platforms have progressed through clinical development. Nevertheless, no pharmacological treatment has been approved as an alternative to the gluten-free diet, and paediatric efficacy and safety data remain limited. In the future, these interventions are most likely to be evaluated as adjuncts to dietary treatment, particularly for protection against inadvertent gluten exposure or for persistent disease activity. Demonstration of sustained mucosal protection, clinically relevant efficacy and long-term safety will be essential before their integration into paediatric practice.

Accedi per visualizzare l'articolo

HOME
PRIVACY POLICY
AREA RISERVATA

SIGENP

Segreteria Amministrativa
c/o BioMedia srl
via Libero Temolo 4
20126, Milano
sigenp@biomedia.net

Designed by Biomedia srl
© 2025 SIGENP
P. IVA IT 09056111009

Login

Recupera password